Immunotherapy for pancreatic cancer: A long and hopeful journey

被引:39
作者
Xu, Jian-wei [1 ]
Wang, Lei [1 ]
Cheng, Yu-gang [1 ]
Zhang, Guang-yong [1 ]
Hu, San-yuan [1 ]
Zhou, Bin [2 ]
Zhan, Han-xiang [1 ]
机构
[1] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Qingdao 266003, Shandong, Peoples R China
关键词
Pancreatic cancer; Immunotherapy; Tumor microenvironment; Vaccines; Monoclonal antibodies; T-CELL-ENGAGER; ALGENPANTUCEL-L IMMUNOTHERAPY; TUMOR-ASSOCIATED MACROPHAGES; STANDARD ADJUVANT THERAPY; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; DOSE-ESCALATION; DENDRITIC CELLS; IMMUNE-SYSTEM; OPEN-LABEL;
D O I
10.1016/j.canlet.2018.03.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple therapeutic strategies have been developed to treat pancreatic cancer, However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. The current review describes the roles of immune cells and the immunosuppressive microenvironment in the development of pancreatic cancer, as well as the preclinical and clinical outcomes and benefits of recent immunotherapeutic approaches, which may help us further disclose the mechanisms of pancreatic cancer progression and the dialectical views of feasibility and effectiveness of immunotherapy in treatment of pancreatic cancer. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 101 条
  • [1] Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
    Abou-Alfa, Ghassan K.
    Chapman, Paul B.
    Feilchenfeldt, Jonas
    Brennan, Murray F.
    Capanu, Marinela
    Gansukh, Bolorsukh
    Jacobs, Gria
    Levin, Adrah
    Neville, Deirdre
    Kelsen, David P.
    O'Reilly, Eileen M.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 321 - 325
  • [2] Big opportunities for small molecules in immuno-oncology
    Adams, Jerry L.
    Smothers, James
    Srinivasan, Roopa
    Hoos, Axel
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) : 603 - 622
  • [3] Vaccinia virus, a promising new therapeutic agent for pancreatic cancer
    Al Yaghchi, Chadwan
    Zhang, Zhongxian
    Alusi, Ghassan
    Lemoine, Nicholas R.
    Wang, Yaohe
    [J]. IMMUNOTHERAPY, 2015, 7 (12) : 1249 - 1258
  • [4] Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
    Amedei, Amedeo
    Niccolai, Elena
    Prisco, Domenico
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3354 - 3368
  • [5] Senolytic CAR T cells reverse senescence-associated pathologies
    Amor, Corina
    Feucht, Judith
    Leibold, Josef
    Ho, Yu-Jui
    Zhu, Changyu
    Alonso-Curbelo, Direna
    Mansilla-Soto, Jorge
    Boyer, Jacob A.
    Li, Xiang
    Giavridis, Theodoros
    Kulick, Amanda
    Houlihan, Shauna
    Peerschke, Ellinor
    Friedman, Scott L.
    Ponomarev, Vladimir
    Piersigilli, Alessandra
    Sadelain, Michel
    Lowe, Scott W.
    [J]. NATURE, 2020, 583 (7814) : 127 - +
  • [6] NATURAL-KILLER-CELL ACTIVITY IN PATIENTS WITH NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL-TRACT - RELATION WITH CIRCULATING GASTROINTESTINAL HORMONES
    APARICIOPAGES, MN
    VERSPAGET, HW
    PENA, AS
    JANSEN, JBMJ
    LAMERS, CBHW
    [J]. NEUROPEPTIDES, 1991, 20 (01) : 1 - 7
  • [7] Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
    Asahara, Shingo
    Takeda, Kazuyoshi
    Yamao, Kenji
    Maguchi, Hiroyuki
    Yamaue, Hiroki
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [8] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Shailubhai, Kunwar
    Bahleda, Rastilav
    Gazzah, Anas
    Varga, Andrea
    Hollebecque, Antoine
    Massard, Christophe
    Spreafico, Anna
    Reni, Michele
    Soria, Jean-Charles
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1257 - 1265
  • [9] Bispecific T-Cell Engaging Antibodies for Cancer Therapy
    Baeuerle, Patrick A.
    Reinhardt, Carsten
    [J]. CANCER RESEARCH, 2009, 69 (12) : 4941 - 4944
  • [10] PD-1 and PD-L1 antibodies in cancer: current status and future directions
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) : 551 - 564